Recombinant PDCD1 (Spartalizumab Biosimilar) antibody
Reactivity: Human
FACS, in vivo
Host: Mouse
Monoclonal
unconjugated
Recombinant Antibody
-
- Target
- PDCD1 (Spartalizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
- Host
- Mouse
- Clonality
- Monoclonal
- Application
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- Purpose
- Spartalizumab Biosimilar, Human PD-1 Monoclonal Antibody
- Specificity
- The in vivo grade spartalizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1), antagonizing its interaction with its known ligands PD-L1 and PD-L2.
- Characteristics
- Recombinant Humanized IgG4 Monoclonal Antibody.
- Purification
- Protein A affinity column
- Purity
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- Sterility
- 0.2 μm filtered
- Endotoxin Level
- < 1 EU per 1 mg of the protein by the LAL method.
- Immunogen
- The anti-human PD-1 monoclonal antibody spartalizumab biosimilar was produced in mammalian cells.
- Isotype
- IgG4 kappa
-
- Application Notes
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by spartalizumab.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 mg/mL
- Buffer
- PBS, pH 7.4, no stabilizers or preservatives.
- Preservative
- Without preservative
- Handling Advice
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- Expiry Date
- 12 months
-
- Target
- PDCD1 (Spartalizumab Biosimilar)
- Target Type
- Biosimilar
- Background
- Spartalizumab Biosimilar uses the same protein sequences as the therapeutic antibody spartalizumab. A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.
-
You are here:
